Drugmakers say they will not start new trials at China military hospitals
Bristol Myers Squibb, Pfizer, Eli Lilly, AbbVie and Merck told the House Select Committee on China they will not open new trial sites in Xinjiang or at military hospitals.
. 1-minute read.

STAT reported on Friday that five large pharmaceutical companies have told the United States House Select Committee on China that they will not open trial locations in Xinjiang or at hospitals tied to the Chinese military. The five companies are the drugmakers Bristol Myers Squibb, Pfizer, Eli Lilly, AbbVie and Merck. Each of these companies said it would not begin new clinical studies at sites connected to the People’s Liberation Army of China, according to the report. The House committee also opened investigations into the five companies last June. Those investigations were prompted by concerns about intellectual property exposure, military ties, and ethical standards at trial sites in sensitive parts of China. In its letters to the companies, the committee also said it was increasingly worried about possible security risks. STAT reported on Friday that the companies told the panel they will halt clinical trials at certain hospitals in China.
Sources: STAT
Corrections. Report an error to corrections@clinicalobserver.com. Read our corrections policy.